These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28854318)

  • 1. Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors.
    Blumenthal DM; Goldman D; Jena AB
    JAMA Cardiol; 2017 Oct; 2(10):1063-1064. PubMed ID: 28854318
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
    Kazi DS; Penko J; Ollendorf DA; Coxson PG; Bibbins-Domingo K
    Ann Intern Med; 2018 Jun; 168(12):896-898. PubMed ID: 29610832
    [No Abstract]   [Full Text] [Related]  

  • 3. PCSK9 inhibitors: smooth sailing or a little turbulence ahead?
    Hegele RA
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):490-492. PubMed ID: 28483371
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
    Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
    Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results.
    Toth PP; Stevens W; Chou JW
    J Med Econ; 2017 Jul; 20(7):749-751. PubMed ID: 28471246
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
    Arrieta A; Page TF; Veledar E; Nasir K
    PLoS One; 2017; 12(1):e0169761. PubMed ID: 28081164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
    Navar AM; Mulder HM; Wojdyla DM; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006019. PubMed ID: 31918581
    [No Abstract]   [Full Text] [Related]  

  • 8. Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.
    Behr PEB; Moriguchi EH; Castro I; Bodanese LC; Dutra OP; Leães PE; Pimentel Filho P
    Arq Bras Cardiol; 2018 Jul; 111(1):104-108. PubMed ID: 30110052
    [No Abstract]   [Full Text] [Related]  

  • 9. PCSK9 inhibitors- A new age in lipid management?
    Grant PJ
    Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
    [No Abstract]   [Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
    Arbel R; Hammerman A; Triki N; Greenberg D
    Int J Cardiol; 2016 Oct; 220():242-5. PubMed ID: 27389448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balanced Dysfunction in the Healthcare Ecosystem Harms Patients.
    Califf RM
    Circulation; 2019 Dec; 140(23):1860-1864. PubMed ID: 31790300
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.
    Shah P
    Curr Cardiol Rep; 2018 May; 20(7):51. PubMed ID: 29779055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 Inhibitors: Economics and Policy.
    Hlatky MA; Kazi DS
    J Am Coll Cardiol; 2017 Nov; 70(21):2677-2687. PubMed ID: 29169476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
    Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
    Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.